Asian consensus report on functional dyspepsia

Journal of Neurogastroenterology and Motility

Volumn 18, Issue 2, 2012, Pages 150-168

  Miwa, Hiroto ^a   Ghoshal, Uday C ^b   Gonlachanvit, Sutep ^c   Gwee, Kok Ann ^d   Ang, Tiing Leong ^e   Chang, Full Young ^f   Fock, Kwong Ming ^e   Hongo, Michio ^g   Hou, Xiaohua ^h   Kachintorn, Udom ⁱ   Ke, Meiyun ^j   Lai, Kwok Hung ^k   Lee, Kwang Jae ^l   Lu, Ching Liang ^f   Mahadeva, Sanjiv ^m   Miura, Soichiro ⁿ   Park, Hyojin ^o   Rhee, Poong Lyul ^p   Sugano, Kentaro ^q   Vilaichone, Ratha Korn ^r   Wong, Benjamin C Y ^s   Bak, Young Tae ^t   more..

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^c CHULALONGKORN UNIVERSITY   (Thailand)

^d Dept Medicine Endocrinol Diabet   (Singapore)

^e CHANGI GENERAL HOSPITAL   (Singapore)

^f TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^g TOHOKU UNIVERSITY HOSPITAL   (Japan)

^h HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

ⁱ MAHIDOL UNIVERSITY   (Thailand)

^j PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^k NATIONAL YANG MING UNIVERSITY   (Taiwan)

^l Ajou University School of Medicine   (South Korea)

^m UNIVERSITY OF MALAYA   (Malaysia)

ⁿ NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^o Yonsei University College of Medicine   (South Korea)

^p Sungkyunkwan University School of Medicine   (South Korea)

^q JICHI MEDICAL UNIVERSITY   (Japan)

^r THAMMASAT UNIVERSITY HOSPITAL   (Thailand)

^s UNIVERSITY OF HONG KONG   (Hong Kong)

^t Korea University College of Medicine   (South Korea)

more..

Author keywords

Asia; Diagnosis; Epidemiology; Functional dyspepsia; Management; Pathophysiology

Indexed keywords

ACOTIAMIDE; AMITRIPTYLINE; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BUSPIRONE; CINITAPRIDE; CISAPRIDE; DOMPERIDONE; FLUOXETINE; HERBACEOUS AGENT; ITOPRIDE; METOCLOPRAMIDE; MOSAPRIDE; PROKINETIC AGENT; PROTON PUMP INHIBITOR; RIKKUNSHITO; SULPIRIDE; TANDOSPIRONE; TJ 43; TRIMEBUTINE; UNCLASSIFIED DRUG; VENLAFAXINE;

ALGORITHM; ARTICLE; ASIA; BACTERIAL OVERGROWTH; BACTERIUM DETECTION; CARDIOVASCULAR DISEASE; COMORBIDITY; CONSENSUS DEVELOPMENT; COST BENEFIT ANALYSIS; DEPRESSION; DIET THERAPY; DRUG MECHANISM; DRUG MEGADOSE; DYSPEPSIA; FECES ANALYSIS; FOOD INTAKE; GASTROINTESTINAL ENDOSCOPY; GENERAL PRACTITIONER; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; LIFESTYLE; LOW DRUG DOSE; MALARIA CONTROL; MEDICAL SPECIALIST; NOMENCLATURE; PATHOPHYSIOLOGY; PATIENT REFERRAL; PRACTICE GUIDELINE; PREVALENCE; PRIMARY MEDICAL CARE; QUALITY OF LIFE; RISK REDUCTION; SIDE EFFECT; SOCIOECONOMICS; STOMACH CANCER; SYMPTOMATOLOGY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 84865171113     PISSN: 20930879     EISSN: 20930887     Source Type: Journal    
DOI: 10.5056/jnm.2012.18.2.150     Document Type: Article

References (196)

1. Colin-Jones D, Bloom B, Bodemar G, et al. Management of dyspepsia: report of a working party. Lancet 1988;331:576-579.
2. Murphy MK, Black NA, Lamping DL, et al. Consensus development methods, and their use in clinical guideline development. Health Technol Assess 1998;2:i-iv, 1-88.
3. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ 2004;328:1490.
4. Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology 2006;130:1466-1479.
5. Tuteja AK, Talley NJ, Joos SK, Tolman KG, Hickam DH. Abdominal bloating in employed adults: prevalence, risk factors, and association with other bowel disorders. Am J Gastroenterol 2008;103:1241-1248.
6. Jiang X, Locke GR 3rd, Choung RS, Zinsmeister AR, Schleck CD, Talley NJ. Prevalence and risk factors for abdominal bloating and visible distention: a population-based study. Gut 2008;57:756-763.
7. Manabe N, Haruma K, Hata J, et al. Clinical characteristics of Japanese dyspeptic patients: is the Rome III classification applicable? Scand J Gastroenterol 2010;45:567-572.
8. Wang A, Liao X, Xiong L, et al. The clinical overlap between functional dyspepsia and irritable bowel syndrome based on Rome III criteria. BMC Gastroenterol 2008;8:43.
9. Suzuki H, Gotoda T, Sasako M, Saito D. Detection of early gastric cancer: misunderstanding the role of mass screening. Gastric Cancer 2006;9:315-319.
10. Ryu E, Kim K, Cho MS, Kwon IG, Kim HS, Fu MR. Symptom clusters and quality of life in Korean patients with hepatocellular carcinoma. Cancer Nurs 2010;33:3-10.
11. Karahocagil MK, Akdeniz H, Sunnetcioglu M, et al. A familial outbreak of fascioliasis in Eastern Anatolia: a report with review of literature. Acta Trop 2011;118:177-183.
12. Grazioli B, Matera G, Laratta C, et al. Giardia lamblia infection in patients with irritable bowel syndrome and dyspepsia: a prospective study. World J Gastroenterol 2006;12:1941-1944.
13. Upatham ES, Viyanant V, Kurathong S, et al. Relationship between prevalence and intensity of Opisthorchis viverrini infection, and clinical symptoms and signs in a rural community in north-east Thailand. Bull World Health Organ 1984;62:451-461.
14. Khuroo NS, Khuroo MS. Gastric ascariasis presenting as unique dyspeptic symptoms in an endemic area. Am J Gastroenterol 2010;105:1675-1677.
15. Chen WX, Zhang WF, Li B, et al. Clinical manifestations of patients with chronic pancreatitis. Hepatobiliary Pancreat Dis Int 2006;5:133-137.
16. Gunsar F, Yilmaz S, Bor S, et al. Effect of hypo- and hyperthyroidism on gastric myoelectrical activity. Dig Dis Sci 2003;48:706-712.
17. Van Vlem B, Schoonjans R, Vanholder R, Vandamme W, De Vos M, Lameire N. Dyspepsia and gastric emptying in chronic renal failure patients. Clin Nephrol 2001;56:302-307.
18. Ashizawa N, Hashimoto T, Miyake T, Shizuku T, Imaoka T, Kinoshita Y. Efficacy of camostat mesilate compared with famotidine for treatment of functional dyspepsia: is camostat mesilate effective? J Gastroenterol Hepatol 2006;21:767-771.
19. Gonlachanvit S, Mahachai V, Chaiwatanarat T, Kullavanijaya P. Lack of effect of Helicobacter pylori on symptom improvement with a prokinetic medication, cisapride, in patients with non-ulcer dyspepsia. J Med Assoc Thai 2005;88:660-667.
20. Vakil N, Moayyedi P, Fennerty MB, Talley NJ. Limited value of alarm features in the diagnosis of upper gastrointestinal malignancy: systematic review and meta-analysis. Gastroenterology 2006;131:390-401.
21. Fock KM, Ang TL. Epidemiology of Helicobacter pylori infection and gastric cancer in Asia. J Gastroenterol Hepatol 2010;25:479-486.
22. Parkman HP, Jones MP. Tests of gastric neuromuscular function. Gastroenterology 2009;136:1526-1543.
23. Ghoshal UC, Singh R, Chang FY, Hou X, Wong BCY, Kachintorn U. Epidemiology of uninvestigated and functional dyspepsia in Asia: facts and fiction. J Neurogastroenterol Motil 2011;17:235-244.
24. Li XB, Liu WZ, Ge ZZ, et al. Analysis of clinical characteristics of dyspeptic symptoms in Shanghai patients. Chin J Dig Dis 2005;6:62-67.
25. Kwan AC, Bao TN, Chakkaphak S, et al. Validation of Rome II criteria for functional gastrointestinal disorders by factor analysis of symptoms in Asian patient sample. J Gastroenterol Hepatol 2003;18:796-802.
26. Kim JS, Lee KJ, Kim JH, Hahm KB, Cho SW. Functional gastrointestinal disorders in patients referred to specialist gastroenterologists in a tertiary hospital. Korean J Neurogastroenterol Motil 2004;10:111-117.
27. Mahadeva S, Chia YC, Vinothini A, Mohazmi M, Goh KL. Cost-effectiveness of and satisfaction with a Helicobacter pylori "test and treat" strategy compared with prompt endoscopy in young Asians with dyspepsia. Gut 2008;57:1214-1220.
28. Wai CT, Yeoh KG, Ho KY, Kang JY, Lim SG. Diagnostic yield of upper endoscopy in Asian patients presenting with dyspepsia. Gastrointest Endosc 2002;56:548-551.
29. awamura A, Adachi K, Takashima T, et al. Prevalence of functional dyspepsia and its relationship with Helicobacter pylori infection in a Japanese population. J Gastroenterol Hepatol 2001;16:384-388.
30. Nakamura R, Saikawa Y, Takahashi T, et al. Retrospective analysis of prognostic outcome of gastric cancer in young patients. Int J Clin Oncol 2011;16:328-334.
31. Ghoshal UC, Tiwari S, Dhingra S, et al. Frequency of Helicobacter pylori and CagA antibody in patients with gastric neoplasms and controls: the Indian enigma. Dig Dis Sci 2008;53:1215-1222.
32. Shah SS, Bhatia SJ, Mistry FP. Epidemiology of dyspepsia in the general population in Mumbai. Indian J Gastroenterol 2001;20:103-106.
33. Ghoshal UC, Abraham P, Bhatt C, et al. Epidemiological and clinical profile of irritable bowel syndrome in India: report of the Indian Society of Gastroenterology Task Force. Indian J Gastroenterol 2008;27:22-28.
34. Okumura T, Tanno S, Ohhira M, Tanno S. Prevalence of functional dyspepsia in an outpatient clinic with primary care physicians in Japan. J Gastroenterol 2010;45:187-194.
35. Hu WH, Wong WM, Lam CL, et al. Anxiety but not depression determines health care-seeking behaviour in Chinese patients with dyspepsia and irritable bowel syndrome: a population-based study. Aliment Pharmacol Ther 2002;16:2081-2088.
36. Hori K, Matsumoto T, Miwa H. Analysis of the gastrointestinal symptoms of uninvestigated dyspepsia and irritable bowel syndrome. Gut Liver 2009;3:192-196.
37. Kitapcioǧlu G, Mandiracioǧlu A, Caymaz Bor C, Bor S. Overlap of symptoms of dyspepsia and gastroesophageal reflux in the community. Turk J Gastroenterol 2007;18:14-19.
38. Lee SY, Lee KJ, Kim SJ, Cho SW. Prevalence and risk factors for overlaps between gastroesophageal reflux disease, dyspepsia, and irritable bowel syndrome: a population-based study. Digestion 2009;79:196-201.
39. Sperber AD. The challenge of cross-cultural, multi-national research: potential benefits in the functional gastrointestinal disorders. Neurogastroenterol Motil 2009;21:351-360.
40. Lu CL, Lang HC, Chang FY, et al. Prevalence and health/social impacts of functional dyspepsia in Taiwan: a study based on the Rome criteria questionnaire survey assisted by endoscopic exclusion among a physical check-up population. Scand J Gastroenterol 2005;40:402-411.
41. Moayyedi P, Mason J. Clinical and economic consequences of dyspepsia in the community. Gut 2002;50(suppl 4):iv10-iv12.
42. Jeong JJ, Choi MG, Cho YS, et al. Chronic gastrointestinal symptoms and quality of life in the Korean population. World J Gastroenterol 2008;14:6388-6394.
43. Hu WH, Lam KF, Wong YH, et al. The Hong Kong index of dyspepsia: a validated symptom severity questionnaire for patients with dyspepsia. J Gastroenterol Hepatol 2002;17:545-551.
44. Mahadeva S, Yadav H, Rampal S, Goh KL. Risk factors associated with dyspepsia in a rural Asian population and its impact on quality of life. Am J Gastroenterol 2010;105:904-912.
45. Mahadeva S, Yadav H, Rampal S, Everett SM, Goh KL. Ethnic variation, epidemiological factors and quality of life impairment associated with dyspepsia in urban Malaysia. Aliment Pharmacol Ther 2010;31:1141-1151.
46. Mahadeva S, Wee HL, Goh KL, Thumboo J. The EQ-5D (Euroqol) is a valid generic instrument for measuring quality of life in patients with dyspepsia. BMC Gastroenterol 2009;9:20.
47. Pan XP, Li YY, Sha WH, Yang FY. Psychological factors in functional dyspepsia and its treatment. Chin J Dig Dis 2000;1:17-20.
48. Mahadeva S, Goh KL. Anxiety, depression and quality of life differences between functional and organic dyspepsia. J Gastroenterol Hepatol 2011;26(suppl 3):49-52.
49. Gwee KA, Lu CL, Ghoshal UC. Epidemiology of irritable bowel syndrome in Asia: something old, something new, something borrowed. J Gastroenterol Hepatol 2009;24:1601-1607.
50. Lee KJ, Kindt S, Tack J. Pathophysiology of functional dyspepsia. Best Pract Res Clin Gastroenterol 2004;18:707-716.
51. Miwa H, Watari J, Fukui H, et al. Current understanding of pathogenesis of functional dyspepsia. J Gastroenterol Hepatol 2011;26(suppl 3):53-60.
52. Mimidis K, Tack J. Pathogenesis of dyspepsia. Dig Dis 2008;26:194-202.
53. Kato M, Nishida U, Nishida M, et al. Pathophysiological classification of functional dyspepsia using a novel drinking-ultrasonography test. Digestion 2010;82:162-166.
54. Tack J. Prokinetics and fundic relaxants in upper functional GI disorders. Curr Opin Pharmacol 2008;8:690-696.
55. Perri F, Clemente R, Festa V, et al. Patterns of symptoms in functional dyspepsia: role of Helicobacter pylori infection and delayed gastric emptying. Am J Gastroenterol 1998;93:2082-2088.
56. Sarnelli G, Caenepeel P, Geypens B, Janssens J, Tack J. Symptoms associated with impaired gastric emptying of solids and liquids in functional dyspepsia. Am J Gastroenterol 2003;98:783-788.
57. Rahim MK, Durr-e-Sabih, Mateen A, Najam-Uddin, Yousaf M. Studies of gastric emptying time in patients with non-ulcer dyspepsia. Nucl Med Commun 2007;28:852-858.
58. Aoki S, Haruma K, Kusunoki H, et al. Evaluation of gastric emptying measured with the 13C-octanoic acid breath test in patients with functional dyspepsia: comparison with ultrasonography. Scand J Gastroenterol 2002;37:662-666.
59. Duan LP, Zheng ZT, Li YN. A study of gastric emptying in non-ulcer dyspepsia using a new ultrasonographic method. Scand J Gastroenterol 1993;28:355-360.
60. Shindo T, Futagami S, Hiratsuka T, et al. Comparison of gastric emptying and plasma ghrelin levels in patients with functional dyspepsia and non-erosive reflux disease. Digestion 2009;79:65-72.
61. Takamori K, Mizuta Y, Takeshima F, et al. Relation among plasma ghrelin level, gastric emptying, and psychologic condition in patients with functional dyspepsia. J Clin Gastroenterol 2007;41:477-483.
62. Chang CS, Chen GH, Kao CH, Wang SJ, Peng SN, Huang CK. The effect of Helicobacter pylori infection on gastric emptying of digestible and indigestible solids in patients with nonulcer dyspepsia. Am J Gastroenterol 1996;91:474-479.
63. Waldron B, Cullen PT, Kumar R, et al. Evidence for hypomotility in non-ulcer dyspepsia: a prospective multifactorial study. Gut 1991;32:246-251.
64. Quartero AO, de Wit NJ, Lodder AC, Numans ME, Smout AJ, Hoes AW. Disturbed solid-phase gastric emptying in functional dyspepsia: a meta-analysis. Dig Dis Sci 1998;43:2028-2033.
65. Tack J, Bisschops R, Sarnelli G. Pathophysiology and treatment of functional dyspepsia. Gastroenterology 2004;127:1239-1255.
66. Talley NJ, Verlinden M, Jones M. Can symptoms discriminate among those with delayed or normal gastric emptying in dysmotility- like dyspepsia? Am J Gastroenterol 2001;96:1422-1428.
67. Wegener M, Börsch G, Schaffstein J, Reuter C, Leverkus F. Frequency of idiopathic gastric stasis and intestinal transit disorders in essential dyspepsia. J Clin Gastroenterol 1989;11:163-168.
68. Tack J, Piessevaux H, Coulie B, Caenepeel P, Janssens J. Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology 1998;115:1346-1352.
69. Piessevaux H, Tack J, Walrand S, Pauwels S, Geubel A. Intragastric distribution of a standardized meal in health and functional dyspepsia: correlation with specific symptoms. Neurogastroenterol Motil 2003;15:447-455.
70. Hou XH, Li Q, Zhu L, Xie X, Chen JD. Correlation of gastric liquid emptying with various thresholds of sensation in healthy controls and patients with functional dyspepsia. Dig Dis Sci 2004;49:188-195.
71. Rhee PL, Kim YH, Son HJ, et al. The etiologic role of gastric hypersensitivity in functional dyspepsia in Korea. J Clin Gastroenterol 1999;29:332-335.
72. Mertz H, Fullerton S, Naliboff B, Mayer EA. Symptoms and visceral perception in severe functional and organic dyspepsia. Gut 1998;42:814-822.
73. Tack J, Caenepeel P, Fischler B, Piessevaux H, Janssens J. Symptoms associated with hypersensitivity to gastric distention in functional dyspepsia. Gastroenterology 2001;121:526-535.
74. Vandenberghe J, Vos R, Persoons P, Demyttenaere K, Janssens J, Tack J. Dyspeptic patients with visceral hypersensitivity: sensitisation of pain specific or multimodal pathways? Gut 2005;54:914-919.
75. Lee KJ, Tack J. Duodenal implications in the pathophysiology of functional dyspepsia. J Neurogastroenterol Motil 2010;16:251-257.
76. Son HJ, Rhee PL, Kim JJ, Koh KC, Paik SW, Rhee JC. Hypersensitivity to acid in ulcer-like functional dyspepsia. Korean J Intern Med 1997;12:188-192.
77. Hammer J, Fuhrer M, Pipal L, Matiasek J. Hypersensitivity for capsaicin in patients with functional dyspepsia. Neurogastroenterol Motil 2008;20:125-133.
78. Li Y, Nie Y, Sha W, Su H. The link between psychosocial factors and functional dyspepsia: an epidemiological study. Chin Med J 2002;115:1082-1084.
79. Chen TS, Luo JC, Chang FY. Psychosocial-spiritual factors in patients with functional dyspepsia: a comparative study with normal individuals having the same endoscopic features. Eur J Gastroenterol Hepatol 2010;22:75-80.
80. Kang SG, Kim HJ, Lee SY, Cha MJ, Hwang HH. A study of anger, alexithymia, and depression in the functional dyspepsia. J Korean Acad Fam Med 2002;23:881-889.
81. Mujakovic S, de Wit NJ, van Marrewijk CJ, et al. Psychopathology is associated with dyspeptic symptom severity in primary care patients with a new episode of dyspepsia. Aliment Pharmacol Ther 2009;29:580-588.
82. Hsu YC, Liou JM, Liao SC, et al. Psychopathology and personality trait in subgroups of functional dyspepsia based on Rome III criteria. Am J Gastroenterol 2009;104:2534-2542.
83. Hojo M, Miwa H, Yokoyama T, et al. Treatment of functional dyspepsia with antianxiety or antidepressive agents: systematic review. J Gastroenterol 2005;40:1036-1042.
84. Lee S, Park M, Choi S, Nah Y, Abbey SE, Rodin G. Stress, coping, and depression in non-ulcer dyspepsia patients. J Psychosom Res 2000;49:93-99.
85. Moon JI, Go EH,Kim SY, Hwang IH. Comparison of stressful life events among peptic ulcer, not ulcer dyspepsia and control groups. J Korean Acad Fam Med 1999;20:804-811.
86. Hui WM, Shiu LP, Lam SK. The perception of life events and daily stress in nonulcer dyspepsia. Am J Gastroenterol 1991;86:292-296.
87. Chen TS, Lee YC, Chang FY, Wu HC, Lee SD. Psychosocial distress is associated with abnormal gastric myoelectrical activity in patients with functional dyspepsia. Scand J Gastroenterol 2006;41:791-796.
88. Cheng C, Hui WM, Lam SK. Coping style of individuals with functional dyspepsia. Psychosom Med 1999;61:789-795.
89. Cheng C, Yang FC, Jun S, Hutton JM. Flexible coping psychotherapy for functional dyspeptic patients: a randomized, controlled trial. Psychosom Med 2007;69:81-88.
90. Ahn MK, Lee SY, Kim YJ. The relationship between functional dyspepsia and family function. J Korean Acad Fam Med 1999;20:917-924.
91. Ochi M, Tominaga K, Iketani T, et al. Perfectionism underlying psychological background correlated with the symptoms of functional dyspepsia. J Gastroenterol 2008;43:699-704.
92. Talley NJ, Meineche-Schmidt V, Paré P, et al. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther 1998;12:1055-1065.
93. Moayyedi P, Soo S, Deeks J, Delaney B, Innes M, Forman D. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006;(4):CD001960.
94. Seno H, Nakase H, Chiba T. Usefulness of famotidine in functional dyspepsia patient treatment: comparison among prokinetic, acid suppression and antianxiety therapies. Aliment Pharmacol Ther 2005;21(suppl 2):32-36.
95. Wong WM, Wong BC, Hung WK, et al. Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients. Gut 2002;51:502-506.
96. Leung WK, Wu JC, Chan FK, et al. Initial treatment with lansoprazole in young dyspeptic patients with negative urea breath test result: a randomized controlled trial with 12-month follow-up. Am J Gastroenterol 2007;102:1483-1488.
97. Tack J, Caenepeel P, Arts J, Lee KJ, Sifrim D, Janssens J. Prevalence of acid reflux in functional dyspepsia and its association with symptom profile. Gut 2005;54:1370-1376.
98. Samsom M, Verhagen MA, vanBerge Henegouwen GP, Smout AJ. Abnormal clearance of exogenous acid and increased acid sensitivity of the proximal duodenum in dyspeptic patients. Gastroenterology 1999;116:515-520.
99. Lee KJ, Demarchi B, Demedts I, Sifrim D, Raeymaekers P, Tack J. A pilot study on duodenal acid exposure and its relationship to symptoms in functional dyspepsia with prominent nausea. Am J Gastroenterol 2004;99:1765-1773.
100. Misra SP, Broor SL. Is gastric acid responsible for the pain in patients with essential dyspepsia? J Clin Gastroenterol 1990;12:624-627.
101. Lambert JR. The role of Helicobacter pylori in nonulcer dyspepsia. A debate - for. Gastroenterol Clin North Am 1993;22:141-151.
102. Jaakkimainen RL, Boyle E, Tudiver F. Is Helicobacter pylori associated with non-ulcer dyspepsia and will eradication improve symptoms? A meta-analysis. BMJ 1999;319:1040-1044.
103. el-Omar E, Penman I, Ardill JE, McColl KE. A substantial proportion of non-ulcer dyspepsia patients have the same abnormality of acid secretion as duodenal ulcer patients. Gut 1995;36:534-538.
104. Sarnelli G, Cuomo R, Janssens J, Tack J. Symptom patterns and pathophysiological mechanisms in dyspeptic patients with and without Helicobacter pylori. Dig Dis Sci 2003;48:2229-2236.
105. Moayyedi P, Soo S, Deeks J, et al. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. BMJ 2000;321:659-664.
106. Laine L, Schoenfeld P, Fennerty MB. Therapy for Helicobacter pyloriin patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials. Ann Intern Med 2001;134:361-369.
107. Miwa H, Hirai S, Nagahara A, et al. Cure of Helicobacter pylori infection does not improve symptoms in non-ulcer dyspepsia patients- a double-blind placebo-controlled study. Aliment Pharmacol Ther 2000;14:317-324.
108. Wong WM, Xiao SD, Hu PJ, et al. Standard treatment for Helicobacter pylori infection is suboptimal in non-ulcer dyspepsia compared with duodenal ulcer in Chinese. Aliment Pharmacol Ther 2005;21:73-81.
109. Moayyedi P, Soo S, Deeks J, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006;(2):CD002096.
110. Jin X, Li YM. Systematic review and meta-analysis from Chinese literature: the association between Helicobacter pylori eradication and improvement of functional dyspepsia. Helicobacter 2007;12:541-546.
111. Mearin F, Perez-Oliveras M, Perello A, et al. Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow-up cohort study. Gastroenterology 2005;129:98-104.
112. Li X, Chen H, Lu H, et al. The study on the role of inflammatory cells and mediators in post-infectious functional dyspepsia. Scand J Gastroenterol 2010;45:573-581.
113. Kindt S, Tertychnyy A, de Hertogh G, Geboes K, Tack J. Intestinal immune activation in presumed post-infectious functional dyspepsia. Neurogastroenterol Motil 2009;21:832-e56.
114. Tack J, Demedts I, Dehondt G, et al. Clinical and pathophysiological characteristics of acute-onset functional dyspepsia. Gastroenterology 2002;122:1738-1747.
115. Camilleri CE, Carlson PJ, Camilleri M, et al. A study of candidate genotypes associated with dyspepsia in a U.S. community. Am J Gastroenterol 2006;101:581-592.
116. Holtmann G, Siffert W, Haag S, et al. G-protein beta 3 subunit 825 CC genotype is associated with unexplained (functional) dyspepsia. Gastroenterology 2004;126:971-979.
117. Tahara T, Arisawa T, Shibata T, et al. Homozygous 825T allele of the GNB3 protein influences the susceptibility of Japanese to dyspepsia. Dig Dis Sci 2008;53:642-646.
118. van Lelyveld N, Linde JT, Schipper M, Samsom M. Candidate genotypes associated with functional dyspepsia. Neurogastroenterol Motil 2008;20:767-773.
119. Oshima T, Nakajima S, Yokoyama T, et al. The G-protein beta3 subunit 825 TT genotype is associated with epigastric pain syndrome- like dyspepsia. BMC Med Genet 2010;11:13.
120. Arisawa T, Tahara T, Shibata T, et al. Genetic polymorphisms of molecules associated with inflammation and immune response in Japanese subjects with functional dyspepsia. Int J Mol Med 2007;20:717-723.
121. Tahara T, Arisawa T, Shibata T, Nakamura M, Wang F, Hirata I. COMT geneval158met polymorphism in patients with dyspeptic symptoms. Hepatogastroenterology 2008;55:979-982.
122. Tahara T, Arisawa T, Shibata T, et al. 779 TC of CCK-1 intron 1 is associated with postprandial syndrome (PDS) in Japanese male subjects. Hepatogastroenterology 2009;56:1245-1248.
123. Arisawa T, Tahara T, Shibata T, et al. Genetic polymorphisms of cyclooxygenase-1 (COX-1) are associated with functional dyspepsia in Japanese women. J Womens Health (Larchmt) 2008;17:1039- 1043.
124. Tahara T, Shibata T, Wang F, et al. A genetic variant of the p22PHOX component of NADPH oxidase C242T is associated with reduced risk of functional dyspepsia in Helicobacter pylori-infected Japanese individuals. Eur J Gastroenterol Hepatol 2009;21:1363-1368.
125. Tahara T, Shibata T, Nakamura M, et al. Homozygous TRPV1 315C influences the susceptibility to functional dyspepsia. J Clin Gastroenterol 2010;44:e1-e7.
126. Watt AH, Lewis DJ, Horne JJ, Smith PM. Reproduction of epigastric pain of duodenal ulceration by adenosine. Br Med J (Clin Res Ed) 1987;294:10-12.
127. Rao SS, Mudipalli RS, Mujica V, Utech CL, Zhao X, Conklin JL. An open-label trial of theophylline for functional chest pain. Dig Dis Sci 2002;47:2763-2768.
128. Barbera R, Feinle C, Read NW. Nutrient-specific modulation of gastric mechanosensitivity in patients with functional dyspepsia. Dig Dis Sci 1995;40:1636-1641.
129. Pilichiewicz AN, Feltrin KL, Horowitz M, et al. Functional dyspepsia is associated with a greater symptomatic response to fat but not carbohydrate, increased fasting and postprandial CCK, and diminished PYY. Am J Gastroenterol 2008;103:2613-2623.
130. Feinle-Bisset C, Horowitz M. Dietary factors in functional dyspepsia. Neurogastroenterol Motil 2006;18:608-618.
131. Lee KJ, Kim JH, Cho SW. Dietary influence on electro-gastrography and association of alterations in gastric myoelectrical activity with symptoms in patients with functional dyspepsia. J Gastroenterol Hepatol 2006;21:59-64.
132. Chua AS, Bekkering M, Rovati LC, Keeling PW. Clinical efficacy and prokinetic effect of the CCK-A antagonist loxiglumide in nonulcer dyspepsia. Ann N Y Acad Sci 1994;713:451-453.
133. Carvalho RV, Lorena SL, Almeida JR, Mesquita MA. Food intol erance, diet composition, and eating patterns in functional dyspepsia patients. Dig Dis Sci 2010;55:60-65.
134. Gonlachanvit S. Are rice and spicy diet good for functional gastrointestinal disorders? J Neurogastroenterol Motil 2010;16:131-138.
135. Hu ML, Wu KL, Chiu YC, Chiu KW, Changchien CS. Effect of ginger on patients with functional dyspepsia. J Gastroenterol Hepatol 2009;24(suppl 1):A31.
136. Feinle-Bisset C, Vozzo R, Horowitz M, Talley NJ. Diet, food intake, and disturbed physiology in the pathogenesis of symptoms in functional dyspepsia. Am J Gastroenterol 2004;99:170-181.
137. Gwee KA, Bak YT, Ghoshal UC, et al. Asian consensus on irritable bowel syndrome. J Gastroenterol Hepatol 2010;25:1189-1205.
138. Harvey RF, Mauad EC, Brown AM. Prognosis in the irritable bowel syndrome: a 5-year prospective study. Lancet 1987;1:963-965.
139. Owens DM, Nelson DK, Talley NJ. The irritable bowel syndrome: long-term prognosis and the physician-patient interaction. Ann Intern Med 1995;122:107-112.
140. Haag S, Senf W, Tagay S, et al. Is there a benefit from intensified medical and psychological interventions in patients with functional dyspepsia not responding to conventional therapy? Aliment Pharmacol Ther 2007;25:973-986.
141. Zhang G, Li Y. Psychological intervention on improvement of depression emotion in patients with functional dyspepsia. Chin J Clin Rehabil 2006;10:160-161.
142. Sheu BS, Lin CY, Lin XZ, Shiesh SC, Yang HB, Chen CY. Long-term outcome of triple therapy in Helicobacter pylori-related nonulcer dyspepsia: a prospective controlled assessment. Am J Gastroenterol 1996;91:441-447.
143. Dhali GK, Garg PK, Sharma MP. Role of anti-Helicobacter pylori treatment in H. pylori-positive and cytoprotective drugs in H. pylori- negative, non-ulcer dyspepsia: results of a randomized, double- blind, controlled trial in Asian Indians. J Gastroenterol Hepatol 1999;14:523-528.
144. Hsu PI, Lai KH, Tseng HH, et al. Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia. Aliment Pharmacol Ther 2001;15:195-201.
145. Ang TL, Fock KM, Teo EK, et al. Helicobacter pylori eradication versus prokinetics in the treatment of functional dyspepsia: a randomized, double-blind study. J Gastroenterol 2006;41:647-653.
146. Gwee KA, Teng L, Wong RK, Ho KY, Sutedja DS, Yeoh KG. The response of Asian patients with functional dyspepsia to eradication of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 2009;21:417-424.
147. Fock KM, Katelaris P, Sugano K, et al. Second Asia-Pacific consensus guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009;24:1587-1600.
148. Correa P, Fontham ET, Bravo JC, et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti- Helicobacter pylori therapy. J Natl Cancer Inst 2000;92:1881-1888.
149. Uemura N, Mukai T, Okamoto S, et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev 1997;6:639-642.
150. Mera R, Fontham ET, Bravo LE, et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut 2005;54: 1536-1540.
151. You WC, Brown LM, Zhang L, et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst 2006;98:974-983.
152. Leung WK, Lin SR, Ching JY, et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut 2004;53:1244-1249.
153. Zhou L, Sung JJ, Lin S, et al. A five-year follow-up study on the pathological changes of gastric mucosa after H. pylori eradication. Chin Med J (Engl) 2003;116:11-14.
154. Fuccio L, Zagari RM, Eusebi LH, et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med 2009;151:121-128.
155. Zhou L. Ten-year follow-up study on the incidence of gastric cancer and the pathological changes of gastric mucosa after H. pylori eradication in China. Gastroenterology 2008;134:A233.
156. Saito D, Boku N, Fujioka T, Fukuda Y. Impact of H. pylori eradication on gastric cancer prevention: endosopic results of the Japanese Intervention Trial (JITHP-Study). A randmized multi- center trial. Gastroenterology 2005;128:A4.
157. Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004 291:187-194.
158. Mahadeva S, Goh KL. Epidemiology of functional dyspepsia: a global perspective. World J Gastroenterol 2006;12:2661-2666.
159. Spechler SJ. Epidemiology and natural history of gastro-oesophageal reflux disease. Digestion 1992;51(suppl 1):24-29.
160. Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997;112:1448-1456.
161. Quigley EM. Functional dyspepsia (FD) and non-erosive reflux disease (NERD): overlapping or discrete entities? Best Pract Res Clin Gastroenterol 2004;18:695-706.
162. Small PK, Loudon MA, Waldron B, Smith D, Campbell FC. Importance of reflux symptoms in functional dyspepsia. Gut 1995;36:189-192.
163. Bolling-Sternevald E, Lauritsen K, Aalykke C, et al. Effect of profound acid suppression in functional dyspepsia: a double-blind, randomized, placebo-controlled trial. Scand J Gastroenterol 2002;37:1395-1402.
164. Blum AL, Arnold R, Stolte M, Fischer M, Koelz HR, The Frosch Study Group. Short course acid suppressive treatment for patients with functional dyspepsia: results depend on Helicobacter pylori status. Gut 2000;47:473-480.
165. Gerson LB, Triadafilopoulos G. A prospective study of oesophageal 24-h ambulatory pH monitoring in patients with functional dyspepsia. Dig Liver Dis 2005;37:87-91.
166. Peura DA, Kovacs TO, Metz DC, Siepman N, Pilmer BL, Talley NJ. Lansoprazole in the treatment of functional dyspepsia: two double- blind, randomized, placebo-controlled trials. Am J Med 2004;116:740-748.
167. Hengels K. Therapeutic efficacy of 15 mg lansoprazole mane in 269 patients suffering from non-ulcer dyspepsia (NUD): a multicentre, randomized, double-blind study. Gut 1998;43:A89.
168. Talley NJ, Lauritsen K. The potential role of acid suppression in functional dyspepsia: the BOND, OPERA, PILOT, and ENCORE studies. Gut 2002;50(suppl 4):iv36-iv41.
169. Wang WH, Huang JQ, Zheng GF, et al. Effects of proton-pump inhibitors on functional dyspepsia: a meta-analysis of randomized placebo-controlled trials. Clin Gastroenterol Hepatol 2007;5:178-185.
170. Gwee KA, Hwang JE, Ho KY, Yeoh KG, Lum CF, Ang PK. In-practice predictors of response to proton pump inhibitor therapy in primary care patients with dyspepsia in an Asian population. J Clin Gastroenterol 2008;42:134-138.
171. Reimer C, Søndergaard B, Hilsted L, Bytzer P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology 2009;137:80-87,87.e1.
172. Niklasson A, Lindström L, Simrén M, Lindberg G, Björnsson E. Dyspeptic symptom development after discontinuationof a proton pump inhibitor: a double-blind placebo-controlled trial. Am J Gastroenterol 2010;105:1531-1537.
173. Lombardo L, Foti M, Ruggia O, Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2010;8:504-508.
174. Hiyama T, Yoshihara M, Matsuo K, et al. Meta-analysis of the effects of prokinetic agents in patients with functional dyspepsia. J Gastroenterol Hepatol 2007;22:304-310.
175. Tack J, Masclee A, Heading R, et al. A dose-ranging, placebo-controlled, pilot trial of Acotiamide in patients with functional dyspepsia. Neurogastroenterol Motil 2009;21:272-280.
176. Matsueda K, Hongo M, Tack J, Aoki H, Saito Y, Kato H. Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia - 100 mg t.i.d. is an optimal dosage. Neurogastroenterol Motil 2010;22:618-e173.
177. Qin F, Huang X, Ren P. Chinese herbal medicine modified xiaoyao san for functional dyspepsia: meta-analysis of randomized controlled trials. J Gastroenterol Hepatol 2009;24:1320-1325.
178. Tatsuta M, Iishi H. Effect of treatment with liu-jun-zi-tang (TJ-43) on gastric emptying and gastrointestinal symptoms in dyspeptic patients. Aliment Pharmacol Ther 1993;7:459-462.
179. Kusunoki H, Haruma K, Hata J, et al. Efficacy of rikkunshito, a traditional Japanese medicine (Kampo), in treating functional dyspepsia. Intern Med 2010;49:2195-2202.
180. Soo S, Forman D, Delaney BC, Moayyedi P. A systematic review of psychological therapies for nonulcer dyspepsia. Am J Gastroenterol 2004;99:1817-1822.
181. Mertz H, Fass R, Kodner A, Yan-Go F, Fullerton S, Mayer EA. Effect of amitriptyline on symptoms, sleep, and visceral perception in patients with functional dyspepsia. Am J Gastroenterol 1998;93:160-165.
182. Dinan TG, Mahmud N, Rathore O, et al. A double-blind placebo- controlled study of buspirone-stimulated prolactin release in non-ulcer dyspepsia - are central serotoninergic responses enhanced? Aliment Pharmacol Ther 2001;15:1613-1618.
183. Chua A, Keating J, Hamilton D, Keeling PW, Dinan TG. Central serotonin receptors and delayed gastric emptying in non-ulcer dyspepsia. BMJ 1992;305:280-282.
184. Dinan TG, Yatham LN, Barry S, Chua A, Keeling PW. Serotonin supersensitivity: the pathophysiologic basis of non-ulcer dyspepsia? A preliminary report of buspirone/prolactin responses. Scand J Gastroenterol 1990;25:541-544.
185. Miwa H, Nagahara A, Tominaga K, et al. Efficacy of the 5-HT1A agonist tandospirone citrate inimproving symptoms of patients with functional dyspepsia: a randomized controlled trial. Am J Gastroenterol 2009;104:2779-2787.
186. van Kerkhoven LA, Laheij RJ, Aparicio N, et al. Effect of the antidepressant venlafaxine in functional dyspepsia: a randomized, double- blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2008;6:746-752.
187. Wu CY, Chou LT, Chen HP, Chang CS, Wong PG, Chen GH. Effect of fluoxetine on symptoms and gastric dysrhythmia in patients with functional dyspepsia. Hepatogastroenterology 2003;50:278-283.
188. Tanum L, Malt UF. Personality traits predict treatment outcome with an antidepressant in patients with functional gastrointestinal disorder. Scand J Gastroenterol 2000;35:935-941.
189. Kang JY, Tay HH, Guan R. Chronic upper abdominal pain: site and radiation in various structural and functional disorders and the effect of various foods. Gut 1992;33:743-748.
190. Pilichiewicz AN, Horowitz M, Holtmann GJ, Talley NJ, Feinle-Bisset C. Relationship between symptoms and dietary patterns in patients with functional dyspepsia. Clin Gastroenterol Hepatol 2009;7:317-322.
191. Feinle-Bisset C, Meier B, Fried M, Beglinger C. Role of cognitive factors in symptom induction following high and low fat meals in patients with functional dyspepsia. Gut 2003;52:1414-1418.
192. Feinle C, Meier O, Otto B, D'Amato M, Fried M. Role of duodenal lipid and cholecystokinin A receptors in the pathophysiology of functional dyspepsia. Gut 2001;48:347-355.
193. Feinle C, Fried M. Duodenal sensitivity to lipids and gastric motility: contribution to functional dyspepsia. Praxis (Bern 1994) 1998;87:1817-1820.
194. Tsai SC, Hsieh JF, Ho YJ, Kao CH. Effects of butter and soybean oils on solid-phase gastric emptying in patients with functional dyspepsia. Abdom Imaging 2000;25:35-37.
195. Barbera R, Feinle C, Read NW. Abnormal sensitivity to duodenal lipid infusion in patients with functional dyspepsia. Eur J Gastroenterol Hepatol 1995;7:1051-1057.
196. Mullan A, Kavanagh P, O'Mahony P, Joy T, Gleeson F, Gibney MJ. Food and nutrient intakes and eating patterns in functional and organic dyspepsia. Eur J Clin Nutr 1994;48:97-105.